Curis (NASDAQ:CRIS – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 1st. Analysts expect Curis to post earnings of ($1.70) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.
Curis (NASDAQ:CRIS – Get Free Report) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.94) by ($0.11). The firm had revenue of $2.09 million for the quarter, compared to the consensus estimate of $2.31 million. Curis had a negative return on equity of 224.75% and a negative net margin of 486.45%. During the same quarter in the prior year, the company posted ($2.40) EPS. On average, analysts expect Curis to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Curis Stock Performance
Shares of Curis stock traded down $0.30 during trading on Tuesday, hitting $5.75. 18,054 shares of the stock were exchanged, compared to its average volume of 32,242. The stock’s fifty day moving average is $8.03 and its 200 day moving average is $10.72. The stock has a market cap of $33.87 million, a PE ratio of -0.66 and a beta of 3.36. Curis has a 12 month low of $3.80 and a 12 month high of $17.49.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on Curis
Curis Company Profile
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Read More
- Five stocks we like better than Curis
- What is an Earnings Surprise?
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- Health Care Stocks Explained: Why You Might Want to Invest
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Dividend Capture Strategy: What You Need to Know
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.